

# Richard C Becker

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7123015/publications.pdf>

Version: 2024-02-01

171  
papers

25,063  
citations

50276

46  
h-index

6654

156  
g-index

176  
all docs

176  
docs citations

176  
times ranked

21556  
citing authors

#	ARTICLE	IF	CITATIONS
1	Differential effect of clopidogrel and ticagrelor on leukocyte count in relation to patient characteristics, biomarkers and genotype: a PLATO substudy. <i>Platelets</i> , 2022, 33, 425-431.	2.3	9
2	Current and novel biomarkers of thrombotic risk in COVID-19: a Consensus Statement from the International COVID-19 Thrombosis Biomarkers Colloquium. <i>Nature Reviews Cardiology</i> , 2022, 19, 475-495.	13.7	180
3	Electronic health record-embedded decision support to reduce stroke risk in patients with atrial fibrillation – Study protocol. <i>American Heart Journal</i> , 2022, 247, 42-54.	2.7	1
4	Point-of-care platelet function tests: relevance to arterial thrombosis and opportunities for improvement. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 51, 1-11.	2.1	15
5	Prognostic impact of baseline inflammatory markers in patients with acute coronary syndromes treated with ticagrelor and clopidogrel. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2021, 10, 153-163.	1.0	12
6	COVID-19 and its sequelae: a platform for optimal patient care, discovery and training. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 51, 587-594.	2.1	32
7	Genetic Modifiers of Hereditary Neuromuscular Disorders and Cardiomyopathy. <i>Cells</i> , 2021, 10, 349.	4.1	3
8	Medical publishing during the COVID-19 pandemic: then and now. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 51, 1101-1106.	2.1	2
9	Factor Xa inhibitors: critical considerations for clinical development and testing. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 52, 397-402.	2.1	4
10	Rivaroxaban versus warfarin in patients with atrial fibrillation enrolled in Latin America: Insights from ROCKET AF. <i>American Heart Journal</i> , 2021, 236, 4-12.	2.7	4
11	Differential modulation of polyunsaturated fatty acids in patients with myocardial infarction treated with ticagrelor or clopidogrel. <i>Cell Reports Medicine</i> , 2021, 2, 100299.	6.5	2
12	Pharmacotherapy for diabetes and stroke risk: Results from ROCKET AF. <i>Heart Rhythm O2</i> , 2021, 2, 215-222.	1.7	1
13	Autonomic dysfunction in SARS-COV-2 infection acute and long-term implications COVID-19 editor’s page series. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 52, 692-707.	2.1	39
14	COVID-19 and biomarkers of thrombosis: focus on von Willebrand factor and extracellular vesicles. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 52, 1010-1019.	2.1	10
15	Termination Based on Event Accrual in Per Protocol Versus Intention to Treat in the ROCKET AF Trial. <i>Journal of the American Heart Association</i> , 2021, 10, e022485.	3.7	0
16	Discussion of talks from the symposium: Factor X: From thrombokinase to oral anti-coagulants and beyond. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 52, 408-413.	2.1	0
17	International COVID-19 biomarkers colloquium. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 52, 983-984.	2.1	1
18	Vascular Smooth Muscle Cells in Aortic Aneurysm: From Genetics to Mechanisms. <i>Journal of the American Heart Association</i> , 2021, 10, e023601.	3.7	60

#	ARTICLE	IF	CITATIONS
19	South Asian-Specific MYBPC3 <sup>Δ</sup> 25bp Deletion Carriers Display Hypercontraction and Impaired Diastolic Function Under Exercise Stress. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 766339.	2.4	1
20	ALCAM predicts future cardiovascular death in acute coronary syndromes: Insights from the PLATO trial. <i>Atherosclerosis</i> , 2020, 293, 35-41.	0.8	5
21	Tissue-level inflammation and ventricular remodeling in hypertrophic cardiomyopathy. <i>Journal of Thrombosis and Thrombolysis</i> , 2020, 49, 177-183.	2.1	46
22	Genetic, clinical, molecular, and pathogenic aspects of the South Asian <sup>Δ</sup> specific polymorphic MYBPC3 <sup>Δ</sup> 25bp variant. <i>Biophysical Reviews</i> , 2020, 12, 1065-1084.	3.2	12
23	COVID-19-associated vasculitis and vasculopathy. <i>Journal of Thrombosis and Thrombolysis</i> , 2020, 50, 499-511.	2.1	222
24	Anticipating the long-term cardiovascular effects of COVID-19. <i>Journal of Thrombosis and Thrombolysis</i> , 2020, 50, 512-524.	2.1	85
25	Bridging Anticoagulation with Mechanical Heart Valves: Current Guidelines and Clinical Decisions. <i>Current Cardiology Reports</i> , 2020, 22, 130.	2.9	5
26	COVID-19 update: Covid-19-associated coagulopathy. <i>Journal of Thrombosis and Thrombolysis</i> , 2020, 50, 54-67.	2.1	529
27	Rationale and design of PROACT Xa: A randomized, multicenter, open-label, clinical trial to evaluate the efficacy and safety of apixaban versus warfarin in patients with a mechanical On-X Aortic Heart Valve. <i>American Heart Journal</i> , 2020, 227, 91-99.	2.7	60
28	Designing Human In Vitro Models for Drug Development. <i>Journal of the American College of Cardiology</i> , 2020, 75, 587-589.	2.8	3
29	Covid-19 treatment update: follow the scientific evidence. <i>Journal of Thrombosis and Thrombolysis</i> , 2020, 50, 43-53.	2.1	45
30	Toward understanding the 2019 Coronavirus and its impact on the heart. <i>Journal of Thrombosis and Thrombolysis</i> , 2020, 50, 33-42.	2.1	23
31	The potential roles of Von Willebrand factor and neutrophil extracellular traps in the natural history of hypertrophic and hypertensive cardiomyopathy. <i>Thrombosis Research</i> , 2020, 192, 78-87.	1.7	3
32	Equilibrative nucleoside transporter 1 gene polymorphisms and clinical outcomes following acute coronary syndromes: findings from the PLATElet inhibition and patient Outcomes (PLATO) study. <i>Platelets</i> , 2019, 30, 579-588.	2.3	4
33	Patient-Reported Satisfaction and Study Drug Discontinuation: Post-Hoc Analysis of Findings from ROCKET AF. <i>Cardiology and Therapy</i> , 2019, 8, 283-295.	2.6	2
34	Association of Blood Pressure Level With Left Ventricular Mass in Adolescents. <i>Hypertension</i> , 2019, 74, 590-596.	2.7	87
35	Interleukin <sup>Δ</sup> 18 in patients with acute coronary syndromes. <i>Clinical Cardiology</i> , 2019, 42, 1202-1209.	1.8	16
36	Antithrombotic Therapy in Atrial Fibrillation and Coronary Artery Disease. <i>New England Journal of Medicine</i> , 2019, 381, 1169-1170.	27.0	2

#	ARTICLE	IF	CITATIONS
37	Prevalence and relevance of abnormal glucose metabolism in acute coronary syndromes: insights from the PLATElet inhibition and patient Outcomes (PLATO) trial. <i>Journal of Thrombosis and Thrombolysis</i> , 2019, 48, 563-569.	2.1	11
38	C-X-C Ligand 16 Is an Independent Predictor of Cardiovascular Death and Morbidity in Acute Coronary Syndromes. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2019, 39, 2402-2410.	2.4	25
39	Preclinical Development of a vWF Aptamer to Limit Thrombosis and Engender Arterial Recanalization of Occluded Vessels. <i>Molecular Therapy</i> , 2019, 27, 1228-1241.	8.2	52
40	Acquired Von Willebrand Syndrome (AVWS) in cardiovascular disease: a state of the art review for clinicians. <i>Journal of Thrombosis and Thrombolysis</i> , 2019, 48, 14-26.	2.1	32
41	The rapid proliferation of solicited content online journals: a quest to disseminate knowledge?. <i>Journal of Thrombosis and Thrombolysis</i> , 2019, 47, 337-344.	2.1	1
42	Efficacy and safety of rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation and a history of cancer: observations from ROCKET AF. <i>European Heart Journal Quality of Care &amp; Clinical Outcomes</i> , 2019, 5, 145-152.	4.0	75
43	Admission Levels of DKK1 (Dickkopf-1) Are Associated With Future Cardiovascular Death in Patients With Acute Coronary Syndromes. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2019, 39, 294-302.	2.4	20
44	Direct factor IXa inhibition with the RNA-aptamer pegnivacogin reduces platelet reactivity in vitro and residual platelet aggregation in patients with acute coronary syndromes. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2019, 8, 520-526.	1.0	14
45	Impact of polyvascular disease on patients with atrial fibrillation: Insights from ROCKET AF. <i>American Heart Journal</i> , 2018, 200, 102-109.	2.7	6
46	Inflammation and coronary artery disease. <i>Coronary Artery Disease</i> , 2018, 29, 429-437.	0.7	38
47	Ischaemic Events and Stent Thrombosis following Planned Discontinuation of Study Treatment with Ticagrelor or Clopidogrel in the PLATO Study. <i>Thrombosis and Haemostasis</i> , 2018, 118, 427-429.	3.4	1
48	A legacy of words. <i>Journal of Thrombosis and Thrombolysis</i> , 2018, 45, 197-199.	2.1	1
49	Efficacy and safety of rivaroxaban compared with warfarin in patients with carotid artery disease and nonvalvular atrial fibrillation: Insights from the ROCKET AF trial. <i>Clinical Cardiology</i> , 2018, 41, 39-45.	1.8	11
50	Translational Implications of Platelets as Vascular First Responders. <i>Circulation Research</i> , 2018, 122, 506-522.	4.5	66
51	Osteoprotegerin Is Associated With Major Bleeding But Not With Cardiovascular Outcomes in Patients With Acute Coronary Syndromes: Insights From the PLATO (Platelet Inhibition and Patient) Trial. <i>Journal of Thrombosis and Thrombolysis</i> , 2018, 45, 197-199.	1.0	1
52	Unraveling the Genetic Basis of Recurrent Venous Thromboembolism. <i>Circulation Genomic and Precision Medicine</i> , 2018, 11, .	3.6	1
53	Prediction of Ambulatory Hypertension Based on Clinic Blood Pressure Percentile in Adolescents. <i>Hypertension</i> , 2018, 72, 955-961.	2.7	19
54	Anticoagulants. <i>Neurosurgery Clinics of North America</i> , 2018, 29, 503-515.	1.7	16

#	ARTICLE	IF	CITATIONS
55	SHIP-AHOY (Study of High Blood Pressure in Pediatrics: Adult Hypertension Onset in Youth). <i>Hypertension</i> , 2018, 72, 625-631.	2.7	40
56	Safety of ticagrelor in patients with baseline conduction abnormalities: A PLATO (Study of Platelet) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	2.7	4
57	Aptamers as Therapeutics. <i>Annual Review of Pharmacology and Toxicology</i> , 2017, 57, 61-79.	9.4	383
58	Balancing the risk of spontaneous ischemic and major bleeding events in acute coronary syndromes. <i>American Heart Journal</i> , 2017, 186, 91-99.	2.7	36
59	Biomarkers and Coronary Lesions Predict Outcomes after Revascularization in Non-“ST-Elevation Acute Coronary Syndrome. <i>Clinical Chemistry</i> , 2017, 63, 573-584.	3.2	26
60	Mental stress-induced left ventricular dysfunction and adverse outcome in ischemic heart disease patients. <i>European Journal of Preventive Cardiology</i> , 2017, 24, 591-599.	1.8	19
61	Growth Differentiation Factor 15 at 1 Month After an Acute Coronary Syndrome Is Associated With Increased Risk of Major Bleeding. <i>Journal of the American Heart Association</i> , 2017, 6, .	3.7	27
62	Efficacy and safety of rivaroxaban versus warfarin in patients from mainland China with nonvalvular atrial fibrillation: A subgroup analysis from the ROCKET AF trial. <i>Thrombosis Research</i> , 2017, 156, 184-190.	1.7	11
63	Platelet-related biomarkers and their response to inhibition with aspirin and p2y12-receptor antagonists in patients with acute coronary syndrome. <i>Journal of Thrombosis and Thrombolysis</i> , 2017, 44, 145-153.	2.1	18
64	Safety and Efficacy of Rivaroxaban in Patients With Cardiac Implantable Electronic Devices: Observations From the ROCKET AF Trial. <i>Journal of the American Heart Association</i> , 2017, 6, .	3.7	8
65	Brain-derived neurotrophic factor rs6265 (Val66Met) polymorphism is associated with disease severity and incidence of cardiovascular events in a patient cohort. <i>American Heart Journal</i> , 2017, 190, 40-45.	2.7	25
66	Reversal of Antithrombotic Therapy. <i>JACC Basic To Translational Science</i> , 2017, 2, 146-148.	4.1	0
67	Relative efficacy and safety of ticagrelor vs clopidogrel as a function of time to invasive management in non-“ST-segment elevation acute coronary syndrome in the PLATO trial. <i>Clinical Cardiology</i> , 2017, 40, 390-398.	1.8	16
68	Efficacy and Safety of Rivaroxaban Versus Warfarin in Patients Taking Nondihydropyridine Calcium Channel Blockers for Atrial Fibrillation (from the ROCKET AF Trial). <i>American Journal of Cardiology</i> , 2017, 120, 588-594.	1.6	36
69	Relation of Risk of Stroke in Patients With Atrial Fibrillation to Body Mass Index (from Patients) Tj ETQq1 1 0.784314 rgBT /Overlock 10	1.6	74
70	Increased Post-procedural Non-gastrointestinal Adverse Events After Outpatient Colonoscopy in High-risk Patients. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 883-891.e9.	4.4	14
71	Outcome of Patients Receiving Thrombolytic Therapy While on Rivaroxaban for Nonvalvular Atrial Fibrillation (from Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared With Vitamin K) Tj ETQq1 1 0.784314 rgBT /Overlock 10 <i>Cardiology</i> , 2017, 120, 1837-1840.	1.6	10
72	Response by Piccini et al to Letters Regarding Article, “Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation” • <i>Circulation</i> , 2016, 134, e7-8.	1.6	1

#	ARTICLE	IF	CITATIONS
73	Translation and Clinical Development of Antithrombotic Aptamers. <i>Nucleic Acid Therapeutics</i> , 2016, 26, 147-155.	3.6	26
74	North American Thrombosis Forum, AF Action Initiative Consensus Document. <i>American Journal of Medicine</i> , 2016, 129, S1-S29.	1.5	24
75	Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: Analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial. <i>American Heart Journal</i> , 2016, 177, 1-8.	2.7	23
76	Use of Dual Antiplatelet Therapy and Patient Outcomes in Those Undergoing Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 1694-1702.	2.9	21
77	Pre-existing anti-PEG antibodies are associated with severe immediate allergic reactions to pegnivacogin, a PEGylated aptamer. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 138, 1712-1715.	2.9	156
78	Use of concomitant aspirin in patients with atrial fibrillation: Findings from the ROCKET AF trial. <i>American Heart Journal</i> , 2016, 179, 77-86.	2.7	51
79	On-Treatment Outcomes in Patients With Worsening Renal Function With Rivaroxaban Compared With Warfarin. <i>Circulation</i> , 2016, 134, 37-47.	1.6	134
80	Measurement tools and antidotes for non-vitamin K oral anticoagulants. <i>Journal of Thrombosis and Thrombolysis</i> , 2016, 41, 233-233.	2.1	0
81	Genome-wide association and Mendelian randomization study of NT-proBNP in patients with acute coronary syndrome. <i>Human Molecular Genetics</i> , 2016, 25, 1447-1456.	2.9	41
82	The biochemistry, enzymology and pharmacology of non-vitamin K anticoagulant drug reversal agents and antidotes. <i>Journal of Thrombosis and Thrombolysis</i> , 2016, 41, 273-278.	2.1	8
83	Native valve disease in patients with non-valvular atrial fibrillation on warfarin or rivaroxaban. <i>Heart</i> , 2016, 102, 1036-1043.	2.9	36
84	Reversal of novel oral anticoagulants. <i>Current Opinion in Pharmacology</i> , 2016, 27, 86-91.	3.5	13
85	Cause of Death and Predictors of All-cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AF. <i>Journal of the American Heart Association</i> , 2016, 5, e002197.	3.7	127
86	Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation. <i>Circulation</i> , 2016, 133, 352-360.	1.6	141
87	Aspirin dosing frequency in the primary and secondary prevention of cardiovascular events. <i>Journal of Thrombosis and Thrombolysis</i> , 2016, 41, 493-504.	2.1	6
88	Effect of the REG1 anticoagulation system versus bivalirudin on outcomes after percutaneous coronary intervention (REGULATE-PCI): a randomised clinical trial. <i>Lancet, The</i> , 2016, 387, 349-356.	13.7	109
89	Growth differentiation factor-15 level predicts major bleeding and cardiovascular events in patients with acute coronary syndromes: results from the PLATO study. <i>European Heart Journal</i> , 2016, 37, 1325-1333.	2.2	137
90	The case for preoperative aspirin administration in patients undergoing elective CABG: is it open or closed?. <i>Annals of Translational Medicine</i> , 2016, 4, S26-S26.	1.7	4

#	ARTICLE	IF	CITATIONS
91	Higher risk of death and stroke in patients with persistent vs. paroxysmal atrial fibrillation: results from the ROCKET-AF Trial. <i>European Heart Journal</i> , 2015, 36, 288-296.	2.2	266
92	Ticagrelor versus clopidogrel in Asian patients with acute coronary syndrome: A retrospective analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial. <i>American Heart Journal</i> , 2015, 169, 899-905.e1.	2.7	91
93	Are at Least 12 Months of Dual Antiplatelet Therapy Needed for All Patients With Drug-Eluting Stents?. <i>Circulation</i> , 2015, 131, 2010-2019.	1.6	5
94	Alternative Calculations of Individual Patient Time in Therapeutic Range While Taking Warfarin: Results From the ROCKET AF Trial. <i>Journal of the American Heart Association</i> , 2015, 4, e001349.	3.7	12
95	The periprocedural management of novel oral anticoagulants in patients with nonvalvular atrial fibrillation: Rationale and a summary of the available evidence from phase 3 clinical trials. <i>American Heart Journal</i> , 2015, 169, 315-322.	2.7	9
96	Efficacy and safety of rivaroxaban in patients with diabetes and nonvalvular atrial fibrillation: The Rivaroxaban Once-daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF Trial). <i>American Heart Journal</i> , 2015, 170, 675-682.e8.	2.7	128
97	Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2015, 373, 823-833.	27.0	951
98	Platelet aggregation and mental stress induced myocardial ischemia: Results from the Responses of Myocardial Ischemia to Escitalopram Treatment (REMIT) study. <i>American Heart Journal</i> , 2015, 169, 496-507.e1.	2.7	15
99	Aspirin dosing in cardiovascular disease prevention and management: an update. <i>Journal of Thrombosis and Thrombolysis</i> , 2015, 40, 499-511.	2.1	7
100	Gastrointestinal Bleeding in Patients With Atrial Fibrillation Treated With Rivaroxaban or Warfarin. <i>Journal of the American College of Cardiology</i> , 2015, 66, 2271-2281.	2.8	159
101	Lower mortality following pulmonary adverse events and sepsis with ticagrelor compared to clopidogrel in the PLATO study. <i>Platelets</i> , 2014, 25, 517-525.	2.3	138
102	A Freeze on Tailored Antiplatelet Therapy?. <i>Circulation</i> , 2014, 129, 2088-2090.	1.6	1
103	Inflammatory Response and Thrombosis in Older Individuals. <i>Seminars in Thrombosis and Hemostasis</i> , 2014, 40, 669-674.	2.7	15
104	Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trial. <i>European Heart Journal</i> , 2014, 35, 3377-3385.	2.2	154
105	Sex Differences in Platelet Reactivity and Cardiovascular and Psychological Response to Mental Stress in Patients With Stable Ischemic Heart Disease. <i>Journal of the American College of Cardiology</i> , 2014, 64, 1669-1678.	2.8	78
106	Use and outcomes of antiarrhythmic therapy in patients with atrial fibrillation receiving oral anticoagulation: Results from the ROCKET AF trial. <i>Heart Rhythm</i> , 2014, 11, 925-932.	0.7	52
107	The pharmacology of novel oral anticoagulants. <i>Journal of Thrombosis and Thrombolysis</i> , 2014, 37, 217-233.	2.1	54
108	The unmet need for philanthropic funding of early career cardiovascular investigators. <i>Journal of Thrombosis and Thrombolysis</i> , 2014, 37, 527-531.	2.1	2



#	ARTICLE	IF	CITATIONS
109	Editor's page. <i>Journal of Thrombosis and Thrombolysis</i> , 2014, 37, 216-216.	2.1	0
110	Structure-function relationships of factor Xa inhibitors: implications for the practicing clinician. <i>Journal of Thrombosis and Thrombolysis</i> , 2014, 37, 234-241.	2.1	7
111	Biomarkers in Relation to the Effects of Ticagrelor in Comparison With Clopidogrel in Non-ST-Elevation Acute Coronary Syndrome Patients Managed With or Without In-Hospital Revascularization. <i>Circulation</i> , 2014, 129, 293-303.	1.6	100
112	The efficacy of ticagrelor is maintained in women with acute coronary syndromes participating in the prospective, randomized, PLATelet inhibition and patient Outcomes (PLATO) trial. <i>European Heart Journal</i> , 2014, 35, 1541-1550.	2.2	70
113	Review of the accumulated PLATO documentation supports reliable and consistent superiority of ticagrelor over clopidogrel in patients with acute coronary syndrome. <i>International Journal of Cardiology</i> , 2014, 170, e59-e62.	1.7	10
114	Factors Associated With Major Bleeding Events. <i>Journal of the American College of Cardiology</i> , 2014, 63, 891-900.	2.8	212
115	Antithrombotic therapy: new areas to understand efficacy and bleeding. <i>Expert Opinion on Therapeutic Targets</i> , 2014, 18, 1-8.	3.4	5
116	Factor IXa as a target for anticoagulation in thrombotic disorders and conditions. <i>Drug Discovery Today</i> , 2014, 19, 1445-1453.	6.4	13
117	Efficacy and Safety of Rivaroxaban Compared With Warfarin Among Elderly Patients With Nonvalvular Atrial Fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). <i>Circulation</i> , 2014, 130, 138-146.	1.6	345
118	Laboratory Assessment of Anti-Coagulant Properties of a Von Willebrand Factor Targeted Aptamer. <i>Blood</i> , 2014, 124, 4279-4279.	1.4	0
119	Outcomes of Discontinuing Rivaroxaban Compared With Warfarin in Patients With Nonvalvular Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2013, 61, 651-658.	2.8	181
120	Consensus and Update on the Definition of On-Treatment Platelet Reactivity to Adenosine Diphosphate Associated With Ischemia and Bleeding. <i>Journal of the American College of Cardiology</i> , 2013, 62, 2261-2273.	2.8	807
121	Response to Letter Regarding Article, "Mechanisms of Bleeding and Approach to Patients With Axial-Flow Left Ventricular Assist Devices". <i>Circulation: Heart Failure</i> , 2012, 5, .	3.9	0
122	Rapidly Regulating Platelet Activity In Vivo With an Antidote Controlled Platelet Inhibitor. <i>Molecular Therapy</i> , 2012, 20, 391-397.	8.2	15
123	Biomarker science: on a theme of personalized medicine. <i>Journal of Thrombosis and Thrombolysis</i> , 2012, 34, 141-142.	2.1	2
124	Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2011, 365, 883-891.	27.0	8,006
125	Heparin-associated anti-Xa activity and platelet-derived prothrombotic and proinflammatory biomarkers in moderate to high-risk patients with acute coronary syndrome. <i>Journal of Thrombosis and Thrombolysis</i> , 2011, 31, 146-153.	2.1	8
126	Early-onset obesity and the unwanted promise of thrombosis. <i>Journal of Thrombosis and Thrombolysis</i> , 2011, 32, 125-128.	2.1	1



#	ARTICLE	IF	CITATIONS
127	The many faces of the contact pathway and their role in thrombosis. <i>Journal of Thrombosis and Thrombolysis</i> , 2011, 32, 9-20.	2.1	40
128	Chromogenic laboratory assays to measure the factor Xa-inhibiting properties of apixaban— an oral, direct and selective factor Xa inhibitor. <i>Journal of Thrombosis and Thrombolysis</i> , 2011, 32, 183-187.	2.1	136
129	Beyond Thrombosis. <i>Chest</i> , 2011, 139, 658-668.	0.8	96
130	Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial. <i>European Heart Journal</i> , 2011, 32, 2933-2944.	2.2	335
131	Platelet P2Y12 receptor antagonist pharmacokinetics and pharmaco -dynamics: A foundation for distinguishing mechanisms of bleeding and anticipated risk for platelet-directed therapies. <i>Thrombosis and Haemostasis</i> , 2010, 103, 535-544.	3.4	39
132	Examining biology and pharmacology-based hypotheses in the PLATO trial. <i>Journal of Thrombosis and Thrombolysis</i> , 2010, 30, 119-120.	2.1	0
133	A clinical cardiology perspective of thrombophilias. <i>Journal of Thrombosis and Thrombolysis</i> , 2010, 30, 378-389.	2.1	1
134	Antiplatelet Therapy in Acute Coronary Syndrome (ACS): Applying New Science to Clinical Decisions. <i>American Journal of Cardiology</i> , 2010, 106, S2-S3.	1.6	7
135	Effect of apixaban, an oral and direct factor Xa inhibitor, on coagulation activity biomarkers following acute coronary syndrome. <i>Thrombosis and Haemostasis</i> , 2010, 104, 976-983.	3.4	55
136	Nucleic acid aptamers as antithrombotic agents: Opportunities in extracellular therapeutics. <i>Thrombosis and Haemostasis</i> , 2010, 103, 586-595.	3.4	48
137	Inhibitory Effects of Ticagrelor Compared With Clopidogrel on Platelet Function in Patients With Acute Coronary Syndromes. <i>Journal of the American College of Cardiology</i> , 2010, 56, 1456-1462.	2.8	339
138	Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. <i>Lancet, The</i> , 2010, 376, 1320-1328.	13.7	709
139	Management of Platelet-Directed Pharmacotherapy in Patients With Atherosclerotic Coronary Artery Disease Undergoing Elective Endoscopic Gastrointestinal Procedures. <i>American Journal of Gastroenterology</i> , 2009, 104, 2903-2917.	0.4	35
140	Thrombogenesis in atrial fibrillation contributing mechanisms and natural history. <i>Journal of Thrombosis and Thrombolysis</i> , 2009, 27, 119-121.	2.1	10
141	Biomarker science: direction for the scientific community. <i>Journal of Thrombosis and Thrombolysis</i> , 2009, 27, 355-357.	2.1	0
142	Pharmacogenetics and safety parameters for platelet P2Y12 receptor antagonists. <i>Journal of Thrombosis and Thrombolysis</i> , 2009, 28, 513-514.	2.1	3
143	Antidote—Controlled Antithrombotic Therapy Targeting Factor IXa and Von Willebrand Factor. <i>Annals of the New York Academy of Sciences</i> , 2009, 1175, 61-70.	3.8	6
144	Biological and pharmacological aspects of perioperative hemorrhagic complications associated with oral platelet-directed antithrombotic agents. <i>Thrombosis Research</i> , 2009, 123, 419-428.	1.7	3

#	ARTICLE	IF	CITATIONS
145	Management of Platelet-Directed Pharmacotherapy in Patients With Atherosclerotic Coronary Artery Disease Undergoing Elective Endoscopic Gastrointestinal Procedures. <i>Journal of the American College of Cardiology</i> , 2009, 54, 2261-2276.	2.8	44
146	Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes. <i>New England Journal of Medicine</i> , 2009, 361, 1045-1057.	27.0	6,019
147	Comparison of ticagrelor, the first reversible oral P2Y12 receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial. <i>American Heart Journal</i> , 2009, 157, 599-605.	2.7	363
148	The importance of VTE prevention after orthopaedic surgery. <i>Lancet, The</i> , 2009, 373, 1661-1662.	13.7	4
149	REG-1, a regimen comprising RB-006, a Factor IXa antagonist, and its oligonucleotide active control agent RB-007 for the potential treatment of arterial thrombosis. <i>Current Opinion in Molecular Therapeutics</i> , 2009, 11, 707-15.	2.8	10
150	Platelet biology for the clinician-scientist: an evolution of understanding. <i>Journal of Thrombosis and Thrombolysis</i> , 2008, 25, 235-237.	2.1	4
151	A rationale for conducting parallel mechanistic studies in clinical trials of pharmacotherapy. <i>Journal of Thrombosis and Thrombolysis</i> , 2008, 25, 300-302.	2.1	2
152	Editor's page: fundamentals in neurocardiology. <i>Journal of Thrombosis and Thrombolysis</i> , 2008, 26, 74-77.	2.1	6
153	The Perioperative Management of Antithrombotic Therapy. <i>Chest</i> , 2008, 133, 299S-339S.	0.8	763
154	Clinical Guide to the Use of Antithrombotic Drugs in Coronary Artery Disease. <i>Circulation</i> , 2008, 118, .	1.6	0
155	The Primary and Secondary Prevention of Coronary Artery Disease. <i>Chest</i> , 2008, 133, 776S-814S.	0.8	234
156	Atherothrombosis at a distance: Contributing role of existing large-burden vascular disease, circulating biosignals and modulating extravascular tissues. <i>Thrombosis Research</i> , 2007, 119, 761-768.	1.7	1
157	Off-target properties of pharmacotherapy and the importance of mechanistic investigations in early clinical phase drug development. <i>Journal of Thrombosis and Thrombolysis</i> , 2007, 23, 159-161.	2.1	2
158	Platelets from genome to proteome and beyond. <i>Journal of Thrombosis and Thrombolysis</i> , 2007, 23, 245-248.	2.1	2
159	Focus on thrombosis. <i>Journal of Thrombosis and Thrombolysis</i> , 2007, 24, 183-222.	2.1	3
160	Effect of the novel direct factor Xa inhibitor DX-9065a on thrombin generation and inhibition among patients with stable atherosclerotic coronary artery disease. <i>Thrombosis Research</i> , 2006, 117, 439-446.	1.7	21
161	Biosignatures in thrombotic disorders. <i>Journal of Thrombosis and Thrombolysis</i> , 2006, 22, 157-158.	2.1	2
162	Patient-Specific Antithrombotic Strategies: Lessons Not Yet Learned from the Renal Insufficiency Paradigm. <i>Journal of Thrombosis and Thrombolysis</i> , 2005, 19, 215-217.	2.1	0

#	ARTICLE	IF	CITATIONS
163	The Importance of Factor Xa Regulatory Pathways in Vascular Thromboresistance: Focus on Protein Z. Journal of Thrombosis and Thrombolysis, 2005, 19, 135-137.	2.1	7
164	Cell-Based Models of Coagulation: A Paradigm in Evolution. Journal of Thrombosis and Thrombolysis, 2005, 20, 65-68.	2.1	32
165	Thrombin: Science and application in clinical practice. American Heart Journal, 2005, 149, S1.	2.7	1
166	Understanding the dynamics of thrombin in cardiovascular disease: Pathobiology and biochemistry for the clinician. American Heart Journal, 2005, 149, S2-S8.	2.7	13
167	Novel constructs for thrombin inhibition. American Heart Journal, 2005, 149, S61-S72.	2.7	8
168	Optimizing Heparin Compounds: A Working Construct for Future Antithrombotic Drug Development. Journal of Thrombosis and Thrombolysis, 2004, 18, 55-58.	2.1	9
169	Factor Xa?Protease Activated Receptor Interface: A Paradigm for Combination Pharmacotherapy. Journal of Thrombosis and Thrombolysis, 2004, 18, 153-155.	2.1	1
170	Coagulopathy and Stroke. , 0, , 152-169.		0
171	Coagulopathy and Stroke. , 0, , 152-169.		1